Gastrointestinal stromal tumours: From KIT to succinate dehydrogenase

Histopathology

Volumn 64, Issue 1, 2014, Pages 53-67

  Doyle, Leona A ^a   Hornick, Jason L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Genotype; KIT; PDGFRA; Prognostication; Sarcoma; Soft tissue tumour; Succinate dehydrogenase; Targeted therapy

Indexed keywords

DASATINIB; IMATINIB; MASITINIB; NILOTINIB; REGORAFENIB; SORAFENIB; SUCCINATE DEHYDROGENASE; SUNITINIB;

CARNEY COMPLEX; CELL CYCLE REGULATION; CELL STRUCTURE; CHROMOSOME 14; CHROMOSOME 14Q; CHROMOSOME 17Q; CHROMOSOME 22; CHROMOSOME 3Q; CHROMOSOME 8Q; DISEASE COURSE; DNA METHYLATION; EXON; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERSTITIAL CELL OF CAJAL; LEIOMYOMA; LEIOMYOSARCOMA; MELANOMA; MITOSIS RATE; MYENTERIC PLEXUS; OVERALL SURVIVAL; PARAGANGLIOMA; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; SPINDLE CELL; THYROID CARCINOMA; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE; WILD TYPE;

GENOTYPE; KIT; PDGFRA; PROGNOSTICATION; SARCOMA; SOFT TISSUE TUMOUR; SUCCINATE DEHYDROGENASE; TARGETED THERAPY;

GASTROINTESTINAL STROMAL TUMORS; GENOTYPE; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; SUCCINATE DEHYDROGENASE;

EID: 84889647247     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12302     Document Type: Review

References (113)

1. Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur. J. Cancer 2005; 41; 2868-2872.
2. Nilsson B, Bumming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005; 103; 821-829.
3. Chan KH, Chan CW, Chow WH et al. Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. World J. Gastroenterol. 2006; 12; 2223-2228.
4. Berg J, McNeer G. Leiomyosarcoma of the stomach: a clinical and pathological study. Cancer 1960; 13; 25-33.
5. Ranchod M, Kempson RL. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum: a pathologic analysis of 100 cases. Cancer 1977; 39; 255-262.
6. Smithwick W, Biesecker JL, Leand PM. Leiomyoblastoma: behavior and prognosis. Cancer 1969; 24; 996-1003.
7. Yagihashi S, Kimura M, Kurotaki H et al. Gastric submucosal tumours of neurogenic origin with neuroaxonal and Schwann cell elements. J. Pathol. 1987; 153; 41-50.
8. Hjermstad BM, Sobin LH, Helwig EB. Stromal tumors of the gastrointestinal tract: myogenic or neurogenic? Am. J. Surg. Pathol. 1987; 11; 383-386.
9. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am. J. Pathol. 1998; 152; 1259-1269.
10. Maeda H, Yamagata A, Nishikawa S et al. Requirement of c-kit for development of intestinal pacemaker system. Development 1992; 116; 369-375.
11. Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995; 373; 347-349.
12. Robinson TL, Sircar K, Hewlett BR, Chorneyko K, Riddell RH, Huizinga JD. Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal. Am. J. Pathol. 2000; 156; 1157-1163.
13. Chi P, Chen Y, Zhang L et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 2010; 467; 849-853.
14. West RB, Corless CL, Chen X et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am. J. Pathol. 2004; 165; 107-113.
15. Tsujimura T, Makiishi-Shimobayashi C, Lundkvist J et al. Expression of the intermediate filament nestin in gastrointestinal stromal tumors and interstitial cells of Cajal. Am. J. Pathol. 2001; 158; 817-823.
16. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279; 577-580.
17. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299; 708-710.
18. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001; 438; 1-12.
19. Rubin BP, Singer S, Tsao C et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001; 61; 8118-8121.
20. Singer S, Rubin BP, Lux ML et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J. Clin. Oncol. 2002; 20; 3898-3905.
21. Taniguchi M, Nishida T, Hirota S et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 1999; 59; 4297-4300.
22. Andersson J, Bumming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 2006; 130; 1573-1581.
23. Cho S, Kitadai Y, Yoshida S et al. Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach. Int. J. Oncol. 2006; 28; 1361-1367.
24. Hirota S, Nishida T, Isozaki K et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J. Pathol. 2001; 193; 505-510.
25. Lux ML, Rubin BP, Biase TL et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol. 2000; 156; 791-795.
26. Lasota J, Corless CL, Heinrich MC et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod. Pathol. 2008; 21; 476-484.
27. Huss S, Kunstlinger H, Wardelmann E et al. A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del). Mod. Pathol. 2013; 26; 1004-1012.
28. Hartmann K, Wardelmann E, Ma Y et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 2005; 129; 1042-1046.
29. Hirota S, Ohashi A, Nishida T et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125; 660-667.
30. Kang HJ, Nam SW, Kim H et al. Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 2005; 24; 1066-1074.
31. Chompret A, Kannengiesser C, Barrois M et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 2004; 126; 318-321.
32. Nishida T, Hirota S, Taniguchi M et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat. Genet. 1998; 19; 323-324.
33. Astolfi A, Nannini M, Pantaleo MA et al. A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Lab. Invest. 2010; 90; 1285-1294.
34. Wozniak A, Sciot R, Guillou L et al. Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes Chromosom. Cancer 2007; 46; l261-l1276.
35. Breiner JA, Meis-Kindblom J, Kindblom LG et al. Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell tumors). Cancer Genet. Cytogenet. 2000; 120; 111-116.
36. Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, Kordek R, Miettinen M. Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet. Cytogenet. 2001; 128; 24-30.
37. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Miettinen M, Knuutila S. High-resolution deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal tract suggests two distinct tumor suppressor loci. Genes Chromosom. Cancer 2000; 27; 387-391.
38. Perrone F, Tamborini E, Dagrada GP et al. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit platelet-derived growth factor receptor alpha gene alterations. Cancer 2005; 104; 159-169.
39. Sabah M, Cummins R, Leader M, Kay E. Loss of heterozygosity of chromosome 9p and loss of p16INK4A expression are associated with malignant gastrointestinal stromal tumors. Mod. Pathol. 2004; 17; 1364-1371.
40. Feakins RM. The expression of p53 and bcl-2 in gastrointestinal stromal tumours is associated with anatomical site, and p53 expression is associated with grade and clinical outcome. Histopathology 2005; 46; 270-279.
41. Romeo S, Debiec-Rychter M, Van Glabbeke M et al. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin. Cancer Res. 2009; 15; 4191-4198.
42. Hur K, Lee HJ, Woo JH, Kim JH, Yang HK. Gene expression profiling of human gastrointestinal stromal tumors according to its malignant potential. Dig. Dis. Sci. 2010; 55; 2561-2567.
43. Tornillo L, Duchini G, Carafa V et al. Patterns of gene amplification in gastrointestinal stromal tumors (GIST). Lab. Invest. 2005; 85; 921-931.
44. Dematteo RP, Ballman KV, Antonescu CR et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) Intergroup phase 2 trial. Ann. Surg. 2013; 258; 422-429.
45. Dematteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373; 1097-1104.
46. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003; 21; 4342-4349.
47. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1, 640 patients. J. Clin. Oncol. 2010; 28; 1247-1253.
48. Cassier PA, Fumagalli E, Rutkowski P et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin. Cancer Res. 2012; 18; 4458-4464.
49. Weisberg E, Wright RD, Jiang J et al. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 2006; 131; 1734-1742.
50. Miranda C, Nucifora M, Molinari F et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin. Cancer Res. 2012; 18; 1769-1776.
51. Nishida T, Kanda T, Nishitani A et al. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci. 2008; 99; 799-804.
52. Liegl B, Kepten I, Le C et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J. Pathol. 2008; 216; 64-74.
53. Lim KH, Huang MJ, Chen LT et al. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. Med. Oncol. 2008; 25; 207-213.
54. Agaram NP, Wong GC, Guo T et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosom. Cancer 2008; 47; 853-859.
55. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368; 1329-1338.
56. Demetri GD, Reichardt P, Kang YK et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381; 295-302.
57. Heinrich MC, Marino-Enriquez A, Presnell A et al. Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. Mol. Cancer Ther. 2012; 11; 1770-1780.
58. Agaimy A, Wunsch PH, Hofstaedter F et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am. J. Surg. Pathol. 2007; 31; 113-120.
59. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am. J. Pathol. 2002; 160; 1567-1572.
60. Kawanowa K, Sakuma Y, Sakurai S et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum. Pathol. 2006; 37; 1527-1535.
61. Muenst S, Thies S, Went P, Tornillo L, Bihl MP, Dirnhofer S. Frequency, phenotype, and genotype of minute gastrointestinal stromal tumors in the stomach: an autopsy study. Hum. Pathol. 2011; 42; 1849-1854.
62. Rossi S, Gasparotto D, Toffolatti L et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am. J. Surg. Pathol. 2010; 34; 1480-1491.
63. Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology 2005; 47; 41-47.
64. Antonescu CR, Romeo S, Zhang L et al. Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy. Am. J. Surg. Pathol. 2013; 37; 385-392.
65. Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am. J. Surg. Pathol. 2009; 33; 218-226.
66. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am. J. Surg. Pathol. 2009; 33; 1401-1408.
67. Espinosa I, Lee CH, Kim MK et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am. J. Surg. Pathol. 2008; 32; 210-218.
68. Medeiros F, Corless CL, Duensing A et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am. J. Surg. Pathol. 2004; 28; 889-894.
69. Kang GH, Srivastava A, Kim YE et al. DOG1 and PKC-theta are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors. Mod. Pathol. 2011; 24; 866-875.
70. Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am. J. Surg. Pathol. 2009; 33; 437-446.
71. Yamamoto H, Kojima A, Nagata S, Tomita Y, Takahashi S, Oda Y. KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue: a clinicopathologic and genetic study of 10 cases. Am. J. Surg. Pathol. 2011; 35; 1287-1295.
72. Miettinen M, Wang ZF, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am. J. Surg. Pathol. 2011; 35; 1712-1721.
73. Doyle LA, Nelson D, Heinrich MC, Corless CL, Hornick JL. Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. Histopathology 2012; 61; 801-809.
74. Wagner AJ, Remillard SP, Zhang YX, Doyle LA, George S, Hornick JL. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod. Pathol. 2013; 26; 289-294.
75. Miettinen M, Killian JK, Wang ZF et al. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am. J. Surg. Pathol. 2013; 37; 234-240.
76. Gill AJ, Chou A, Vilain RE, Clifton-Bligh RJ. 'Pediatric-type' gastrointestinal stromal tumors are SDHB negative ('type 2') GISTs. Am. J. Surg. Pathol. 2011; 35; 1245-1247.
77. Rege TA, Wagner AJ, Corless CL, Heinrich MC, Hornick JL. 'Pediatric-type' gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior. Am. J. Surg. Pathol. 2011; 35; 495-504.
78. Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 2005; 5; 857-866.
79. Burnichon N, Briere JJ, Libe R et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum. Mol. Genet. 2010; 19; 3011-3020.
80. Killian JK, Kim SY, Miettinen M et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013; 3; 648-657.
81. Mason EF, Hornick JL. Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: implications for mechanisms of tumorigenesis. Mod. Pathol. 2013; 26; 1492-1497.
82. Kelly L, Bryan K, Kim SY et al. Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor (GIST). PLoS One 2013; 8; e64102.
83. Lasota J, Wang Z, Kim SY, Helman L, Miettinen M. Expression of the receptor for type I insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications. Am. J. Surg. Pathol. 2013; 37; 114-119.
84. Pantaleo MA, Astolfi A, Di Battista M et al. Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int. J. Cancer 2009; 125; 2991-2994.
85. Tarn C, Rink L, Merkel E et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc. Natl Acad. Sci. USA 2008; 105; 8387-8392.
86. Agaram NP, Laquaglia MP, Ustun B et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin. Cancer Res. 2008; 14; 3204-3215.
87. Janeway KA, Zhu MJ, Barretina J, Perez-Atayde A, Demetri GD, Fletcher JA. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int. J. Cancer 2010; 127; 2718-2722.
88. Astuti D, Latif F, Dallol A et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet. 2001; 69; 49-54.
89. Astuti D, Douglas F, Lennard TW et al. Germline SDHD mutation in familial phaeochromocytoma. Lancet 2001; 357; 1181-1182.
90. Baysal BE, Ferrell RE, Willett-Brozick JE et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287; 848-851.
91. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet. 2000; 26; 268-270.
92. McWhinney SR, Pasini B, Stratakis CA, International Carney Triad Carney-Stratakis Syndrome Consortium. Familial gastrointestinal stromal tumors and germ-line mutations. N. Engl. J. Med. 2007; 357; 1054-1056.
93. Pasini B, McWhinney SR, Bei T et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur. J. Hum. Genet. 2008; 16; 79-88.
94. Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am. J. Med. Genet. 2002; 108; 132-139.
95. Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin. Proc. 1999; 74; 543-552.
96. Carney JA, Sheps SG, Go VL, Gordon H. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N. Engl. J. Med. 1977; 296; 1517-1518.
97. Carney JA. Carney triad: a syndrome featuring paraganglionic, adrenocortical, and possibly other endocrine tumors. J. Clin. Endocrinol. Metab. 2009; 94; 3656-3662.
98. Gill AJ, Chou A, Vilain R et al. Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am. J. Surg. Pathol. 2010; 34; 636-644.
99. Matyakhina L, Bei TA, McWhinney SR et al. Genetics of Carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. J. Clin. Endocrinol. Metab. 2007; 92; 2938-2943.
100. Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J. Intern. Med. 2009; 266; 43-52.
101. Zhang L, Smyrk TC, Young WF Jr, Stratakis CA, Carney JA. Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am. J. Surg. Pathol. 2010; 34; 53-64.
102. Oudijk L, Gaal J, Korpershoek E et al. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. Mod. Pathol. 2013; 26; 456-463.
103. Dwight T, Benn DE, Clarkson A et al. Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors. Am. J. Surg. Pathol. 2013; 37; 226-233.
104. Marrari A, Wagner AJ, Hornick JL. Predictors of response to targeted therapies for gastrointestinal stromal tumors. Arch. Pathol. Lab. Med. 2012; 136; 483-489.
105. Kolb EA, Gorlick R. Development of IGF-IR inhibitors in pediatric sarcomas. Curr. Oncol. Rep. 2009; 11; 307-313.
106. Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J. Clin. Oncol. 2010; 28; 4985-4995.
107. Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am. J. Surg. Pathol. 2006; 30; 90-96.
108. Miettinen M, Kopczynski J, Makhlouf HR et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am. J. Surg. Pathol. 2003; 27; 625-641.
109. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am. J. Surg. Pathol. 2006; 30; 477-489.
110. Novelli M, Rossi S, Rodriguez-Justo M et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 2010; 57; 259-270.
111. Agaimy A, Terracciano LM, Dirnhofer S et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J. Clin. Pathol. 2009; 62; 613-616.
112. Hostein I, Faur N, Primois C et al. BRAF mutation status in gastrointestinal stromal tumors. Am. J. Clin. Pathol. 2010; 133; 141-148.
113. Falchook GS, Trent JC, Heinrich MC et al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget 2013; 4; 310-315.